ECM
KDNY

Element Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Element Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-64,578
Closed -$912K – 73
2021
Q2 		$912K Buy
+64,578
New +$1.03M 0.14% 52

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Element Capital Management's KDNY Position: Q3 2021 in Review

Element Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2021, closing a stake of 64,578 shares — an estimated $912K sold.

Element Capital Management first reported a position in KDNY in Q2 2021 and held it in 1 quarter. The position peaked at $912K in Q2 2021. 85 funds tracked by Wall St. Rank hold KDNY as of Q3 2021.

  • Element Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Element Capital Management sold 64,578 Chinook Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $912K.
  • Element Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Element Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $912K in Q2 2021.
  • 85 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Element Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.